SCHEMBL1626115

SCHEMBL1626115

CCOC(=O)C(C(=O)OCC)C(=O)C(C)(C)c1cccc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.42
ALDH1A1 P00352 5/20 0.42
GAA P10253 3/20 0.42
NPC1 O15118 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SCN5A Q14524 3/20 0.40
SCN9A Q15858 3/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
MAOB P27338 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
CNR2 P34972 2/20 0.39
KDM4E B2RXH2 4/20 0.39
THRB P10828 1/20 0.39
KIF11 P52732 1/20 0.39
MAPK1 P28482 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1626321 0.86 MAPT (0.40) MAPTALDH1A1GAANPC1NPSR1
SCHEMBL1625659 0.83 ALDH1A1 (0.41) MAPTALDH1A1GAAKDM4EMAPK1
SCHEMBL1627104 0.83 ALDH1A1 (0.46) MAPTALDH1A1GAANPSR1KDM4E
SCHEMBL1625401 0.83 KCNN4 (0.42) MAPTALDH1A1NPC1NPSR1TRPM8
SCHEMBL1624647 0.82 CYP3A4 (0.48) MAPTALDH1A1GAACNR2MEN1
SCHEMBL1627161 0.82 PIN1 (0.46) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL1625472 0.82 TSHR (0.43) MAPTALDH1A1NPSR1CNR2KDM4E
SCHEMBL1626109 0.81 L3MBTL1 (0.40) NPC1CNR2KDM4EMEN1LMNA
SCHEMBL1625483 0.79 AKR1C3 (0.38) ALDH1A1NPSR1CNR2HPGDTSHR
SCHEMBL1626441 0.78 AKR1C3 (0.39) MAPTNPSR1CNR2MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 US disclosed
EP-2111399-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF Amgen Inc. (US) 2009-10-28 EP disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 US disclosed
WO-2008076427-A2 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN MAPT 4316/4885ALDH1A1 128/4885GAA 347/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN MAPT 4316/4885ALDH1A1 128/4885GAA 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.